SCHEMBL280585

SCHEMBL280585

COCc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.63

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.63
TACR1 P25103 14/20 0.49
CACNA1F O60840 1/20 0.45
CACNA1D Q01668 1/20 0.45
CACNA1S Q13698 1/20 0.45
CACNA1C Q13936 1/20 0.45
CACNA1H O95180 1/20 0.42
SLC6A4 P31645 1/20 0.39
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16956459 0.88 IDO1 (0.50) IDO1TACR1CACNA1FCACNA1DCACNA1S
SCHEMBL25112325 0.86 IDO1 (0.48) IDO1TACR1CACNA1FCACNA1DCACNA1S
SCHEMBL4977101 0.86 IDO1 (0.53) IDO1TACR1CACNA1FCACNA1DCACNA1S
SCHEMBL25112281 0.83 IDO1 (0.50) IDO1TACR1CACNA1FCACNA1DCACNA1S
SCHEMBL20905127 0.82 IDO1 (0.44) IDO1TACR1CACNA1FCACNA1DCACNA1S
SCHEMBL20698868 0.82 IDO1 (0.44) IDO1TACR1CACNA1H
SCHEMBL4975333 0.80 IDO1 (0.43) IDO1ALDH1A1
SCHEMBL171782 0.79 IDO1 (0.68) IDO1SLC6A4
SCHEMBL791992 0.79 GABRA1 (0.48) IDO1TACR1
SCHEMBL5779082 0.78 IDO1 (0.48) IDO1TACR1CACNA1FCACNA1DCACNA1S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023121939-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-06-29 WO disclosed
US-10807951-B2 mTORC1 modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-10-20 US disclosed
WO-2019075386-A1 MTORC1 MODULATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-04-18 WO disclosed
US-20190112268-A1 mTORC1 MODULATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-04-18 US disclosed
EP-2704568-B1 DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES MERCK SHARP & DOHME (US) 2018-01-24 EP disclosed
WO-2017190038-A1 ANALOGS OF YOHIMBINE AND USES THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2017-11-02 WO disclosed
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2017-07-20 US disclosed
US-9272987-B2 Diazeniumdiolate cyclohexyl derivatives MERCK SHARP & DOHME CORP. (US) 2016-03-01 US disclosed
US-20140088048-A1 DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-03-27 US disclosed
US-8133994-B2 Preparation of aprepitant DR. REDDY'S LABORATORIES LTD. (IN) 2012-03-13 US disclosed
US-20110094321-A1 PREPARATION OF APREPITANT DR. REDDY'S LABORATORIES LIMITED (IN) 2011-04-28 US disclosed
US-7872022-B2 Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety HOFFMANN-LA ROCHE INC. (US) 2011-01-18 US disclosed
US-20080009506-A1 Imidazole Compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-01-10 US disclosed
WO-2007113153-A1 PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-11 WO disclosed
EP-1442019-B1 AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2007-10-10 EP disclosed
US-20070232652-A1 Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety HOFFMAN-LA ROCHE INC. 2007-10-04 US disclosed
EP-1451153-B1 NK1 ANTAGONISTS SCHERING CORP (US) 2007-09-26 EP disclosed
US-7183288-B2 Amide derivatives as glycogen synthase kinase 3-β inhibitors FREYNE EDDY JEAN EDGARD 2007-02-27 US disclosed
US-7183288-B2 Amide derivatives as glycogen synthase kinase 3-β inhibitors FREYNE EDDY JEAN EDGARD 2007-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME HSPH1, HBZ, PITHD1 IDO1 3581/4885TACR1 4286/4885CACNA1F 4657/4885
US-20070232652-A1 Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety SLC6A4, SLC6A1, SLC1A2 IDO1 619/4885TACR1 71/4885CACNA1F 1174/4885
US-20110094321-A1 PREPARATION OF APREPITANT KIT, CPA3, CMA1 IDO1 1622/4885TACR1 5/4885CACNA1F 2135/4885
US-20080009506-A1 Imidazole Compound KCNH2, KCNJ2, KCNH3 IDO1 350/4885TACR1 470/4885CACNA1F 40/4885
US-20190112268-A1 mTORC1 MODULATORS MTOR, RPTOR, RICTOR IDO1 3976/4885TACR1 4699/4885CACNA1F 3703/4885
US-20140088048-A1 DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES CBR3, OR10J3, CBR1 IDO1 781/4885TACR1 281/4885CACNA1F 1227/4885
US-10807951-B2 mTORC1 modulators MTOR, RPTOR, RICTOR IDO1 3976/4885TACR1 4699/4885CACNA1F 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.